Life Sciences and Healthcare

Predictive analytics yield better disease forecasting: the example of MS

The possibilities Disease forecasts are market analytics, aimed at understanding and predicting a product’s market potential. Prediction modelling usually involves a prediction profile (algorithm) from past studies. The model is then “deployed” so that a new individual can get a prediction instantly for whatever the need be, such as an epidemiological endpoint. Predictions can range from […]

Impactability is the next step for predictive analytics

As health organizations shift from reactive to preventative care, many decide to focus on analyzing patients’ risk of succumbing to certain conditions. Organizations typically assign a “risk score” for each patient to allow clinicians to easily assess which patients are at a higher risk of an event that may require intervention. While such initiatives typically […]

Everything old is new again: bacteriophage therapy

According to conventional wisdom, if you let children play in the dirt, they get sick less frequently. As is often the case, science appears to back up this homespun theory. Now that many disease-inducing pathogens are developing antibacterial resistance, scientists and medical professionals are looking for answers that may literally be beneath their feet. Bacteriophages […]

Migraine: a revolution in prevention

This article is a Clarivate Analytics Market Insight report, an ongoing series featuring expert reviews of hot topics in the pharma/biotech field, with analysis and discussion on the factors currently affecting the industry. The migraine market has seen little movement for many years, with no new therapies entering the space either for acute treatment or […]

The latest plague outbreak in Sub-Saharan Africa

There is currently an outbreak of both pneumonic and bubonic plague in Madagascar. This crisis situation was the focus of a November 6 report affirming the countrywide spread of the plague epidemic, with disease cases growing by 37% over five days, from 1,309 to 1,801, according to the World Health Organization (WHO).  As Madagascar enters […]

The impact of the changing regulatory environment on the approval of new medicines, 2007-2016

Over the last decade, 2007-2016, convergence in approval times as well as changes in strategies of multinational pharmaceuticals have resulted in more new active substances (NASs) being internationalized, referring here to receiving marketing authorization in six major regulatory agencies, namely the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), the Japan Pharmaceuticals […]

Green light to market Hemlibra for hemophilia A with inhibitors in the US

This article is a Clarivate Analytics Market Insight report, an ongoing series featuring expert reviews of hot topics in the pharma/biotech field, with analysis and discussion on the factors currently affecting the industry.   Roche Holding’s Hemlibra (emicizumab-kxvh) has been approved in the U.S. for routine prophylaxis to prevent or reduce the frequency of bleeding […]

Will an Effective Drug Ever Reach the Market for Geographic Atrophy?

Roche/Genentech’s lampalizumab fails Phase III development for geographic atrophy Genentech reported on November 9, 2017 that lampalizumab failed to meet the primary end point for reducing mean change in geographic atrophy (GA) lesion area compared with sham treatment at one year in CHROMA, its second Phase III trial in GA.1 Although these results are not […]